Research
Hormonal
Obesity-related hypertension is mechanistically driven by visceral fat accumulation, leading to SNS and RAAS activation, sodium retention, and inflammation, which directly causes CKD progression.
Visceral fat is not just storage; it actively drives high blood pressure and kidney damage through hormones and inflammation. Managing visceral fat is key to preventing kidney disease.
StrongSupportsVERY_HIGH confidence
Various factors, including the sympathetic nervous system, renin-angiotensin-aldosterone system, and inflammatory pathways, are intricately involved in the pathogenesis of obesity-related hypertension. These factors individually and jointly contribute to the development of hypertension (usually sodium-sensitive or resistant hypertension) and, ultimately, to the progression of CKD.
Why this rating
Comprehensive review of multiple pathways.
Source
Obesity-related hypertension and chronic kidney disease: from evaluation to management
Mi‐Hyang Jung et al. · Kidney Research and Clinical Practice · 2023
DOI 10.23876/j.krcp.23.072
narrative_reviewCited 19×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Intensive lifestyle modifications, specifically combining calorie-reduced/low-sodium diets (e.g., DASH) with regular exercise, are the foundational first-line management strategy for obesity-related hypertension, aiming for 5-10% body weight loss.Good
- Semaglutide (2.4 mg weekly) and Liraglutide (3 mg daily) are effective pharmacological interventions for obesity-related hypertension, with Semaglutide showing superior weight loss and blood pressure reduction compared to Liraglutide.Good
- Bariatric surgery (specifically gastric bypass) is a highly effective intervention for obesity-related hypertension, capable of inducing hypertension remission in over half of patients and significantly reducing antihypertensive medication use.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →